The FDA decision on ONS-5010 in May 2026 is the binary catalyst. Approval could drive significant upside; another CRL would likely be devastating given the $7.7M cash position and ongoing operating losses. The adjusted EPS miss and declining European sales add near-term pressure. Monitor the FDA decision closely, this is a high-risk, binary event stock.
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 18 $0.2290entry
- T+1 · 6mo ago −0.44%α +0.23% · $0.2280
- T+5 · 6mo ago +74.67%α +73.06% · $0.4000
- T+20 · 5mo ago +585.59%α +584.01% · $1.57
- T+60 · 3mo ago +288.21%α +282.63% · $0.8890
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Outlook Therapeutics reported Q2 FY2026 results with GAAP net loss of $0.05/share (vs consensus $-0.12) and adjusted net loss of $0.16/share (vs consensus $-0.12). Revenue was $128K from initial LYTENAVA sales in Europe, but unit sales declined ~10% QoQ. The company completed a formal FDA dispute resolution meeting in April and expects a decision in May 2026, while cash stood at $7.7M (pre-April $4.2M offering).
Key Financial Metrics
Key Facts
- GAAP net loss per share: $(0.05) vs consensus $(0.12), beat on GAAP basis due to $9.3M in non-cash gains (warrant liability + promissory note fair value changes)
- Adjusted (non-GAAP) net loss per share: $(0.16) vs consensus $(0.12), miss of 33% on the Street metric
- Revenue: $128K from LYTENAVA European sales, down ~10% QoQ from Dec 2025 quarter
- Cash and equivalents: $7.7M as of March 31, 2026 (excluding $4.2M net from April 2026 registered direct offering)
- FDA formal dispute resolution meeting completed in April 2026; decision expected in May 2026
- Convertible promissory note restructured with maturity extended to December 2026
- March 2026 public offering raised ~$4.0M net; April 2026 registered direct offering raised $4.2M net
Financial Impact
Adjusted EPS miss of ~33% vs consensus; revenue of $128K with QoQ decline; cash runway extended by recent offerings but still limited
Risk Factors
- FDA decision expected May 2026, negative outcome could render stock near-zero given limited cash
- Cash burn continues with only $7.7M (pre-April offering), additional dilution likely
- European LYTENAVA unit sales declined ~10% QoQ despite early launch momentum
- High share count dilution: weighted average shares rose from 30.9M to 81.8M YoY
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3296119 |
Track record
37 reports on OTLK
13 of 22 bullish or bearish reports moved the stock their way by T+5. Best: +306.25% at T+20 after the May 26, 2026 report. 17 of 22 went positive at some point.
Filters
- Oct 13, 20264w ago SC 13G Neutral 4/10 Entry $0.5638 to $0.5200 Now $0.3960 −29.76% ▼ −7.77% −6.62% vs SPY
- Oct 6, 20265w ago Press Release Neutral 3/10 Entry $0.5720 to $0.5638 Now $0.3960 −30.77% ▼ −1.43% −1.29% vs SPY
- Sep 18, 20268w ago 8-K Neutral 3/10 Entry $0.6863 to $0.6211 Now $0.3960 −42.30% ▼ −9.50% −8.48% vs SPY
- Aug 14, 202613w ago 8-K Bearish 6/10 Entry $0.7564 to $0.6472 Now $0.3960 +47.65% ▲ +14.44% +13.07% vs SPY
- Aug 14, 202613w ago 424B5 Bearish 7/10 Entry $0.7564 to $0.6472 Now $0.3960 +47.65% ▲ +14.44% +13.07% vs SPY
- Aug 14, 202613w ago 8-K Bearish 6/10 No price data
- Aug 14, 202613w ago Press Release Mixed 7/10 Entry $0.7564 to $0.6472 Now $0.3960 −47.65% ▼ −14.44% −13.07% vs SPY
- Aug 12, 202613w ago Press Release Bearish 7/10 Entry $0.8888 to $0.6763 Now $0.3960 +55.45% ▲ +23.91% +21.94% vs SPY
- Aug 12, 202613w ago 8-K Bearish 7/10 Entry $0.8888 to $0.6763 Now $0.3960 +55.45% ▲ +23.91% +21.94% vs SPY
- Jul 24, 202616w ago 8-K Bullish 8/10 Entry $1.07 to $0.9766 Now $0.3960 −62.82% ▼ −8.30% −9.37% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers